Literature DB >> 24371224

Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.

Craig W Menges1, Yuwaraj Kadariya1, Deborah Altomare2, Jacqueline Talarchek1, Erin Neumann-Domer1, Yue Wu1,3, Guang-Hui Xiao3, Irina M Shapiro4, Vihren N Kolev4, Jonathan A Pachter4, Andres J Klein-Szanto1, Joseph R Testa1.   

Abstract

Malignant mesothelioma is a highly aggressive, asbestos-related cancer frequently marked by mutations of both NF2 and CDKN2A. We demonstrate that germline knockout of one allele of each of these genes causes accelerated onset and progression of asbestos-induced malignant mesothelioma compared with asbestos-exposed Nf2(+/-) or wild-type mice. Ascites from some Nf2(+/-);Cdkn2a(+/-) mice exhibited large tumor spheroids, and tail vein injections of malignant mesothelioma cells established from these mice, but not from Nf2(+/-) or wild-type mice, produced numerous tumors in the lung, suggesting increased metastatic potential of tumor cells from Nf2(+/-);Cdkn2a(+/-) mice. Intraperitoneal injections of malignant mesothelioma cells derived from Nf2(+/-);Cdkn2a(+/-) mice into severe combined immunodeficient mice produced tumors that penetrated the diaphragm and pleural cavity and harbored increased cancer stem cells (CSC). Malignant mesothelioma cells from Nf2(+/-);Cdkn2a(+/-) mice stained positively for CSC markers and formed CSC spheroids in vitro more efficiently than counterparts from wild-type mice. Moreover, tumor cells from Nf2(+/-);Cdkn2a(+/-) mice showed elevated c-Met expression/activation, which was partly dependent on p53-mediated regulation of miR-34a and required for tumor migration/invasiveness and maintenance of the CSC population. Collectively, these studies demonstrate in vivo that inactivation of Nf2 and Cdkn2a cooperate to drive the development of highly aggressive malignant mesotheliomas characterized by enhanced tumor spreading capability and the presence of a CSC population associated with p53/miR-34a-dependent activation of c-Met. These findings suggest that cooperativity between losses of Nf2 and Cdkn2a plays a fundamental role in driving the highly aggressive tumorigenic phenotype considered to be a hallmark of malignant mesothelioma. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24371224      PMCID: PMC3945416          DOI: 10.1158/0008-5472.CAN-13-2062

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Authors:  Chang-Il Hwang; Andres Matoso; David C Corney; Andrea Flesken-Nikitin; Stefanie Körner; Wei Wang; Carla Boccaccio; Snorri S Thorgeirsson; Paolo M Comoglio; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-09       Impact factor: 11.205

2.  Inhibition of the met receptor in mesothelioma.

Authors:  Toru Mukohara; Gabriel Civiello; Ian J Davis; Michele L Taffaro; James Christensen; David E Fisher; Bruce E Johnson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

3.  The MET oncogene is a functional marker of a glioblastoma stem cell subtype.

Authors:  Francesca De Bacco; Elena Casanova; Enzo Medico; Serena Pellegatta; Francesca Orzan; Raffaella Albano; Paolo Luraghi; Gigliola Reato; Antonio D'Ambrosio; Paola Porrati; Monica Patanè; Emanuela Maderna; Bianca Pollo; Paolo M Comoglio; Gaetano Finocchiaro; Carla Boccaccio
Journal:  Cancer Res       Date:  2012-06-26       Impact factor: 12.701

4.  MET signaling regulates glioblastoma stem cells.

Authors:  Kyeung Min Joo; Juyoun Jin; Eunhee Kim; Kang Ho Kim; Yonghyun Kim; Bong Gu Kang; Youn-Jung Kang; Justin D Lathia; Kwang Ho Cheong; Paul H Song; Hyunggee Kim; Ho Jun Seol; Doo-Sik Kong; Jung-Il Lee; Jeremy N Rich; Jeongwu Lee; Do-Hyun Nam
Journal:  Cancer Res       Date:  2012-05-22       Impact factor: 12.701

5.  Identification of cancer stem cell markers in human malignant mesothelioma cells.

Authors:  Farhana Ishrat Ghani; Hiroto Yamazaki; Satoshi Iwata; Toshihiro Okamoto; Keisuke Aoe; Kazunori Okabe; Yusuke Mimura; Nobukazu Fujimoto; Takumi Kishimoto; Taketo Yamada; C Wilson Xu; Chikao Morimoto
Journal:  Biochem Biophys Res Commun       Date:  2010-12-14       Impact factor: 3.575

6.  A mouse model recapitulating molecular features of human mesothelioma.

Authors:  Deborah A Altomare; Charles A Vaslet; Kristine L Skele; Assunta De Rienzo; Karthik Devarajan; Suresh C Jhanwar; Andrea I McClatchey; Agnes B Kane; Joseph R Testa
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

Review 7.  microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review).

Authors:  May Y W Wong; Yan Yu; William R Walsh; Jia-Lin Yang
Journal:  Int J Oncol       Date:  2011-03-10       Impact factor: 5.650

8.  Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.

Authors:  Ryan Morrison; Stephen M Schleicher; Yunguang Sun; Kenneth J Niermann; Sungjune Kim; Daniel E Spratt; Christine H Chung; Bo Lu
Journal:  J Oncol       Date:  2010-10-12       Impact factor: 4.375

9.  Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma.

Authors:  Shih-Hwa Chiou; Cheng-Chia Yu; Chi-Yang Huang; Shu-Chun Lin; Chung-Ji Liu; Tung-Hu Tsai; Shiu-Huey Chou; Chian-Shiu Chien; Hung-Hai Ku; Jeng-Fan Lo
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

10.  Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma.

Authors:  Brock C Christensen; John J Godleski; Carmen J Marsit; E A Houseman; Cristina Y Lopez-Fagundo; Jennifer L Longacker; Raphael Bueno; David J Sugarbaker; Heather H Nelson; Karl T Kelsey
Journal:  Carcinogenesis       Date:  2008-02-28       Impact factor: 4.944

View more
  25 in total

Review 1.  MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets.

Authors:  Glen Reid
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.

Authors:  Di Wen; Yang Peng; Feng Lin; Rakesh K Singh; Ram I Mahato
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

3.  Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Authors:  Irina M Shapiro; Vihren N Kolev; Christian M Vidal; Yuwaraj Kadariya; Jennifer E Ring; Quentin Wright; David T Weaver; Craig Menges; Mahesh Padval; Andrea I McClatchey; Qunli Xu; Joseph R Testa; Jonathan A Pachter
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

4.  Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.

Authors:  Jinfei Xu; Yuwaraj Kadariya; Mitchell Cheung; Jianming Pei; Jacqueline Talarchek; Eleonora Sementino; Yinfei Tan; Craig W Menges; Kathy Q Cai; Samuel Litwin; Hongzhuang Peng; Jayashree Karar; Frank J Rauscher; Joseph R Testa
Journal:  Cancer Res       Date:  2014-06-13       Impact factor: 12.701

Review 5.  Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance.

Authors:  Joseph J Sacco; Michael J Clague
Journal:  Transl Lung Cancer Res       Date:  2015-06

6.  Expression characteristics of long non-coding RNA in colon adenocarcinoma and its potential value for judging the survival and prognosis of patients: bioinformatics analysis based on The Cancer Genome Atlas database.

Authors:  Ruofan Li; Xu Gao; Haitao Sun; Lixin Sun; Xiaojian Hu
Journal:  J Gastrointest Oncol       Date:  2022-06

7.  Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.

Authors:  Eleonora Sementino; Craig W Menges; Yuwaraj Kadariya; Suraj Peri; Jinfei Xu; Zemin Liu; Richard G Wilkes; Kathy Q Cai; Frank J Rauscher; Andres J Klein-Szanto; Joseph R Testa
Journal:  J Cell Physiol       Date:  2018-06-15       Impact factor: 6.384

8.  Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma.

Authors:  Yuwaraj Kadariya; Craig W Menges; Jacqueline Talarchek; Kathy Q Cai; Andres J Klein-Szanto; Ralph A Pietrofesa; Melpo Christofidou-Solomidou; Mitchell Cheung; Brooke T Mossman; Arti Shukla; Joseph R Testa
Journal:  Cancer Prev Res (Phila)       Date:  2016-03-02

9.  Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.

Authors:  Anna-Mariya Kukuyan; Eleonora Sementino; Yuwaraj Kadariya; Craig W Menges; Mitchell Cheung; Yinfei Tan; Kathy Q Cai; Michael J Slifker; Suraj Peri; Andres J Klein-Szanto; Frank J Rauscher; Joseph R Testa
Journal:  Cancer Res       Date:  2019-05-31       Impact factor: 13.312

Review 10.  Mouse models for mesothelioma drug discovery and development.

Authors:  Kenneth P Seastedt; Nathanael Pruett; Chuong D Hoang
Journal:  Expert Opin Drug Discov       Date:  2020-12-31       Impact factor: 7.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.